Zasocitinib for adults with nonsegmental vitiligo
Treatments studied
Part of Skin clinical trials.
This trial tests an oral medication called zasocitinib to see if it can help repigment skin in adults with nonsegmental vitiligo. It may be an option for people whose vitiligo covers a moderate amount of their body and who have not had certain recent treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have nonsegmental vitiligo (the kind that appears on both sides of the body).
- Your vitiligo covers at least 5% of your body, but not more than 50%.
- You have not used light therapy or certain skin-bleaching treatments in the past 8 weeks.
- You are willing to use effective birth control if needed, or are past childbearing years.
- You do not have active infections, a history of certain heart problems, or unstable medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational pill called povorcitinib phosphate to see if it can help repigment skin in adults with nonsegmental vitiligo. It is a phase 3 trial in China, and participants will stop other vitiligo treatments during the study.
This study tests a cream called ruxolitinib for children with nonsegmental vitiligo. It aims to see if the cream can safely help restore skin color in affected areas.
This study tests an experimental medication (ACT-777991) taken by mouth to see if it can help repigment skin in adults with non-segmental vitiligo. It aims to learn how safe it is and how well it works.
This trial tests a daily pill (upadacitinib) to see if it can improve vitiligo after an initial treatment (NECS). It is for people whose vitiligo is stable and covers a limited area.
This study tests an investigational drug (GIA632) in people with non-segmental vitiligo. It aims to see if different doses can safely and effectively restore color to white patches.
This study tests a new medication called FXS5626 to help treat non-segmental vitiligo (a type of vitiligo that affects both sides of the body). It is for people who have moderate to large patches of vitiligo, especially on the face.
Hear when a new NonSegmental Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.